Sutro Biopharma Inc is committed to revolutionizing the discovery, development, and manufacturing of next-generation protein therapeutics. Their corporate philosophy centers around leveraging their proprietary technology platform to deliver innovative solutions for patients with unmet medical needs. Sutro Biopharma emphasizes collaboration, integrity, and scientific excellence in all aspects of their operations. By focusing on strategic partnerships, they aim to accelerate the development of novel drug candidates and bring them to market efficiently. With their expertise in protein engineering, Sutro Biopharma is dedicated to transforming the landscape of biopharmaceuticals through their pioneering approach.

Sutro Biopharma Inc is primarily present in the United States and Europe.

Sutro Biopharma Inc has achieved several significant milestones. The company successfully completed its initial public offering in September 2018, raising approximately $85 million. In 2019, Sutro Biopharma initiated its first clinical trial for STRO-001, an antibody-drug conjugate targeting cancer. The company also entered into key strategic collaborations, including a collaboration with Merck to develop multiple undisclosed immuno-oncology therapies. Sutro Biopharma's proprietary XpressCF™ and XpressCF+™ platforms have enabled efficient and rapid discovery and development of novel molecules, showcasing the company's technological advancements. Moreover, Sutro Biopharma has been recognized for its innovation and progress within the biopharmaceutical industry.

Sutro Biopharma Inc is a biopharmaceutical company focused on developing innovative cancer therapeutics. Founded in 2003 in California, Sutro Biopharma's mission is to revolutionize the treatment of cancer by leveraging its proprietary cell-free protein synthesis technology. With this cutting-edge platform, the company designs and develops best-in-class antibody-drug conjugates (ADCs) and bispecific antibodies, aiming to address the unmet needs of patients with challenging tumor types. Backed by an experienced team and strategic partnerships, Sutro Biopharma has made significant advancements in its pipeline and is committed to advancing novel treatments for cancer patients worldwide.

The main competitors of Sutro Biopharma Inc in the market include companies such as Amgen Inc., Genentech, Inc., and AstraZeneca plc.

Sutro Biopharma Inc is primarily active in the biopharmaceutical industry.

Sutro Biopharma Inc operates with a unique business model focused on developing and commercializing novel protein therapeutics. As a biopharmaceutical company, Sutro Biopharma leverages its proprietary cell-free protein synthesis platform to design and manufacture next-generation antibody-drug conjugates (ADCs) and bispecific antibodies. By utilizing its innovative technology, Sutro Biopharma aims to accelerate the discovery and development of targeted therapies to address various unmet medical needs. The company's business model emphasizes strategic partnerships and collaborations to advance its pipeline and expand its reach in the biopharmaceutical market. Sutro Biopharma Inc remains committed to driving advancements in the field of biotechnology through its distinctive approach.

Az Sutro Biopharma P/E mutatója -0,84.

Az Sutro Biopharma KUV 3,09.

Az AlleAktien Minőségi Score Sutro Biopharma esetében 3/10.

A várt Sutro Biopharma forgalma 67,38 Mió. USD.

A(z) várt Sutro Biopharma nyereség -247,06 Mió. USD.

Sutro Biopharma Inc. is a San Francisco-based biotechnology company specializing in the development of innovative cancer therapies. The company utilizes a unique technology platform to develop novel therapeutic antibodies and antibody-drug conjugates (ADCs) that have the potential to revolutionize cancer treatment. Sutro Biopharma's business model includes three main divisions: research and development, clinical trials, and partnerships with other pharmaceutical and biotechnology companies. The company aims to provide its customers and partners with innovative cancer treatments while also meeting the demand for personalized therapies. Research and Development: Sutro Biopharma has developed a unique technology platform called XpressCF+ that allows the company to develop customized antibodies for cancer therapy. The technology is based on a unique system that allows for the production of antibodies directly within cells. This enables Sutro Biopharma to rapidly and effectively develop and optimize antibody candidates. Clinical Trials: Sutro Biopharma has several promising cancer drugs in the clinical phase of development, including STRO-002, an antibody-drug conjugate targeting the folate receptor-alpha (FRα) antigen, which is overexpressed in many solid tumors. The company's clinical trials have shown that STRO-002 can be highly effective in severe and advanced cancer. Partnerships with Other Pharmaceutical and Biotechnology Companies: Sutro Biopharma has formed partnerships with major pharmaceutical and biotechnology companies such as Merck, Celgene, and EMD Serono to utilize its technology platform and promising antibody candidates. Sutro Biopharma receives upfront and milestone payments for conducting research and development tasks, as well as licensing fees and revenue sharing if their products are successfully brought to market. Products: Sutro Biopharma offers various products in the field of cancer therapy, including antibody-drug conjugates (ADCs), antibodies against novel target structures, and other cancer therapeutics. STRO-001, another antibody-drug conjugate targeting the CD74 antigen, is also being tested in clinical development. Conclusion: Sutro Biopharma has made significant progress in cancer therapy with its unique technology platform and promising antibody candidates. The company's business model includes research and development, clinical trials, and partnerships with other pharmaceutical and biotechnology companies. By combining these divisions, the company has the potential to revolutionize cancer therapy and improve the lives of cancer patients.

A(z) Sutro Biopharma évente alkalommal oszt ki 0 USD összegű osztalékot.

A Sutro Biopharma esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Sutro Biopharma ISIN kódja: US8693671021.

A Sutro Biopharma WKN-je A2N6SG.

Az Sutro Biopharma tőzsdei rövidítése STRO.

Az elmúlt 12 hónapban a(z) Sutro Biopharma osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Sutro Biopharma várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Sutro Biopharma jelenlegi osztalékhozama .

A(z) Sutro Biopharma negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Sutro Biopharma az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Sutro Biopharma a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Sutro Biopharma által 2024. 10. 01.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 10. 01.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 10. 01. időpontban történt.

2023 évben a Sutro Biopharma 0 USD összegű osztalékot fizetett ki.

Az Sutro Biopharma osztalékait USD fizeti ki.